Kelly Hosmer

Kelly Hosmer currently serves as the Global Brand & US Marketing Lead for HAE at Intellia Therapeutics, Inc., beginning in January 2025. Prior to this role, Kelly held multiple positions at bluebird bio from September 2017 to May 2024, including Senior Director, US Brand Lead, where responsibilities included leading the successful launch of ex-vivo HSC gene therapies like ZYNTEGLO and SKYSONA. Additional roles at bluebird bio involved oversight of marketing strategies and launch preparations for FDA approvals. Kelly's previous experience includes positions at Bioverativ, Biogen, and Cambridge BioMarketing, with an extensive focus on marketing within the biopharmaceutical sector. Educational achievements include an MBA in Health Sector Management from Duke University and a BS in Business Administration from Boston University.